Male Breast Cancer and 5α-Reductase Inhibitors Finasteride and Dutasteride

    November 2013 in “ The Journal of Urology
    Steven T. Bird, James M. Brophy, Abraham G. Hartzema, Joseph A. Delaney, Mahyar Etminan
    Image of study
    TLDR Using finasteride or dutasteride does not increase the risk of male breast cancer.
    The study, which included 339 male breast cancer cases and 6,780 controls from a population of men aged 40-85 years in the United States between 2001-2009, found no significant association between the use of 5-alpha-reductase inhibitors (5ARIs), finasteride and dutasteride, and the risk of developing male breast cancer. Rate ratios (RR) for breast cancer with 5ARI exposure were not significant for various exposure assessment periods, including ≥1 year (RR 0.70), ≥2 years (RR 0.59), and ≥3 years (RR 0.75), as well as for each subsequent 180 days (RR 1.02) and 365 days (RR 1.03) of cumulative therapy. The study concluded that the risk of breast cancer should not affect the decision to prescribe 5ARI therapy for other conditions.
    View this study on →

    Cited in this study

    2 / NoResults


    6 / NoResults